A new study in the journal JAMA Network Open has found the rate of Guillain–Barré syndrome (GBS) amongst those "vaccinated" with the J&J injection is "significantly higher than the background rate."
Due to concerns with the risk of thrombosis with thrombocytopenia syndrome (TTS), the FDA is limiting the authorized use of the Johnson & Johnson...